Novavax: The Beaten-Down COVID-19 Darling
Novavax Inc NVAX
$7.32
▼ -1.61%
($-0.12)
🔥 High Short Interest
🎢 High Beta
📅 Earnings This Week
Open
$7.44
Prev Close
$7.44
Day Range
$7.22 – $7.49
52W Range
$6.20 – $11.97
Market Cap
$1.20B
P/E (TTM)
2.73
Beta
2.50
EPS (TTM)
$-0.61
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1973-05-16 |
| Shares Out. | 164,440,000 |
| Website | novavax.com/?locale=US ↗ |
| Phone | 12402682000 |
| Employees | 749 |
| Revenue | $139.5M |
| Gross Profit | $108.8M |
| Net Income | -$9.5M |
| Free Cash Flow | -$97.6M |
| Total Assets | $1.04B |
| Total Liabilities | $1.19B |
| Equity | -$144.8M |
About Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Novavax Inc is a publicly traded company under the ticker symbol NVAX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)